Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 25.5 -0.51% -0.13
RYTM closed down 0.51 percent on Thursday, March 4, 2021, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical RYTM trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -0.51%
Oversold Stochastic Weakness -0.51%
Earnings Movers Other -4.71%
Wide Bands Range Expansion -4.71%
Oversold Stochastic Weakness -4.71%
Older End-of-Day Signals for RYTM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 22 hours ago
200 DMA Support about 22 hours ago
Down 2 % about 22 hours ago
10 DMA Resistance about 23 hours ago
Up 2% about 23 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Rhythm Pharmaceuticals, Inc. Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Peptides Metabolic Disorders Peptide Hormones Genetic Disorder Genetic Disorders Monogenic Homeostasis Leptin Melanocortin

Is RYTM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 43.23
52 Week Low 12.99
Average Volume 464,277
200-Day Moving Average 25.18
50-Day Moving Average 30.88
20-Day Moving Average 28.73
10-Day Moving Average 26.30
Average True Range 1.95
ADX 24.16
+DI 18.27
-DI 29.90
Chandelier Exit (Long, 3 ATRs ) 29.58
Chandelier Exit (Short, 3 ATRs ) 30.47
Upper Bollinger Band 34.49
Lower Bollinger Band 22.97
Percent B (%b) 0.22
BandWidth 40.07
MACD Line -1.64
MACD Signal Line -1.41
MACD Histogram -0.2326
Fundamentals Value
Market Cap 1.13 Billion
Num Shares 44.2 Million
EPS -3.34
Price-to-Earnings (P/E) Ratio -7.63
Price-to-Sales 0.00
Price-to-Book 7.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.56
Resistance 3 (R3) 27.64 27.05 27.21
Resistance 2 (R2) 27.05 26.52 27.00 27.10
Resistance 1 (R1) 26.27 26.20 26.66 26.19 26.98
Pivot Point 25.68 25.68 25.87 25.63 25.68
Support 1 (S1) 24.90 25.15 25.29 24.82 24.02
Support 2 (S2) 24.31 24.83 24.26 23.90
Support 3 (S3) 23.53 24.31 23.79
Support 4 (S4) 23.45